Ann: Investor Presentation - April 2022, page-4

I received this from a broker today. Tipping there is news to come very soon with David doing a NON_DEAL roadshow around Oz for next two weeks. $$$$

Pleased join us for drinks and dinner at Steve’s Bar in Nedlands, for a Presentation by HeraMED Limited. Invitation attached

Date: Thursday 28^th April 2022 at 5pm

HeraMED Limited (ASX:HMD) is an innovative medical data and technology company that is leading the digital transformation of the prenatal and postpartum experience with its revolutionary remote monitoring and hybrid maternity care platform.

Presenters:

● HeraMED CEO and Co-founder David Groberman

● Dr Cliff Neppe, Head of Obstetrics at Joondalup Health Campus, the first Hospital globally to adopt HeraMED’s innovative remote care monitoring platform and hear how the hospital is changing the standard of care for pregnancy

Reasons to attend:

● Understand how HeraMED’s connected maternity care platform works

● Find out how HeraMED’s medically optimized and smartphone-based HeraCARE provides seamless data sharing remoting vital foetal and material measurements with medical professionals

● Get an update on how HeraMED is being adopted by medical leaders around the world

● Learn about the growing pipeline of global commercial opportunities underpinned by continued remote monitoring tailwinds accelerated by the Covid-19 pandemic

● Discover how HeraMED’s recent commercial agreement with JHC (part of Ramsay Health Care) provides financial model validation and a pathway to commercial scalability

Recent highlights

• A joint Virtual OB Paid Pilot between HeraMED and US-based Pediatrix Medical Group, an affiliate of Mednax Inc., has been well-received by patients and providers, reducing office visits while providing the same or superior-level care (April 2022)

• Joondalup Health Campus (JHC) in Western Australia completed a successful pilot and entered into an agreement for a full commercial rollout of the HeraCARE solution as the primary standard of care offered for expecting mothers. The contract value for the first 12 months is expected to be approximately A$220k (January 2022)

• HeraCARE pilot with US-based Obstetrix Medical Group, leaders in women’s and children’s healthcare provides very positive interim results, adherence levels and feedback from expectant mothers as well as clinicians (September 2021)

• Sheba Medical Center, the largest hospital in Israel and the Middle East, expanded its cutting-edge FemTech pilot program to test both the HeraBEAT device and HeraCARE platform amongst women with high-risk pregnancies (August 2021)

Roadshow focus areas

• Focus on the key markets of the US, Australia, EU and Israel, increasing the Company’s client base and medical partnerships

• Drive wider adoption and improved revenues

• Foster a well-defined commercialisation strategy to further expand the pipeline of opportunities, underpinned by the fast-track adoption of telehealth worldwide

• Continue optimising the HeraMED platform, working closely with global leading medical partners to fully understand their current and future needs

“We believe competitiveness in our sector will be determined by the ability to prove significant value to both expecting mothers as well as physicians. HeraCARE is an advanced and comprehensive home pregnancy solution and we plan to keep its winning edge by offering advanced, clinically-proven technology.”

• HeraMED CEO and Co-founder David Groberman

HeraMED Share Price Data (as at 22 April 2022)

GICS: Health Care Equipment & Services

ASX code: HMD

ASX Listing Date: 12 December 2018

Market cap: $30.24m

Share price: $0.155

52-week high: $0.120

52-week low $0.335

Average volume 242,098

Useful links

Company website

Latest investor presentation

ASX announcements